Cargando…
Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting
BACKGROUND: The 5-year survival rate of patients with metastatic gastric cancer (GC) is only 5%. However, trials have demonstrated promising antitumor activity for targeted therapies/immunotherapies among chemorefractory metastatic GC patients. Pembrolizumab has shown particular efficacy among patie...
Autores principales: | Lauren, Brianna, Ostvar, Sassan, Silver, Elisabeth, Ingram, Myles, Oh, Aaron, Kumble, Lindsay, Laszkowska, Monika, Chu, Jacqueline N., Hershman, Dawn L., Manji, Gulam, Neugut, Alfred I., Hur, Chin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048937/ https://www.ncbi.nlm.nih.gov/pubmed/32148492 http://dx.doi.org/10.1155/2020/2198960 |
Ejemplares similares
-
Association of Neighborhood Deprivation Index With Success in Cancer Care Crowdfunding
por: Silver, Elisabeth R., et al.
Publicado: (2020) -
Racial and ethnic disparities in mortality from gastric and esophageal adenocarcinoma
por: Laszkowska, Monika, et al.
Publicado: (2020) -
Cost‐effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab‐paclitaxel in borderline resectable/locally advanced pancreatic cancer patients
por: Ingram, Myles A., et al.
Publicado: (2022) -
Prevalence of Clostridioides difficile and Other Gastrointestinal Pathogens in Patients with COVID-19
por: Laszkowska, Monika, et al.
Publicado: (2021) -
The timing of cranial radiation in elderly patients with newly diagnosed glioblastoma multiforme
por: Lai, Rose, et al.
Publicado: (2010)